Blocking of the endothelin system: The development of receptor antagonists

Pulmonary Pharmacology and Therapeutics

Volumn 11, Issue 2-3, 1998, Pages 97-112

  Battistini, B ^a   Dussault, P ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; 3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ATRASENTAN; CYCLO(DEXTRO GLUTAMYLALANYL DEXTRO ALLO ISOLEUCYLLEUCYL DEXTRO TRYPTOPHYL); CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE; NITRIC OXIDE; PD 155719; PD 159433; PD 166114; PD 180988; SULFANILAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZD 2574;

ANTIBACTERIAL ACTIVITY; BRONCHOSPASM; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; KIDNEY VASCULAR RESISTANCE; LUNG DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR AFFINITY; RECEPTOR BINDING; STROKE; VASOCONSTRICTION;

EID: 0032056204     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1998.0154     Document Type: Conference Paper

References (137)

1. 1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
2. 2. Battistini B, Dussault P. Biosynthesis, Distribution and Metabolism of Endothelins in the Pulmonary System. Pulm Pharmacol Ther 1998; 11: 79-88.
3. 3. Turner A J, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 1997; 11: 355-364.
4. 4. Battistini B, Warner T D. Effects of endothelins: Endothelin-induced responses in the pulmonary system. In: Huggins, J P, Pelton J T eds. Endothelins in Biology and Medicine. CRC Press, 1997; 191-222.
5. 5. Battistini B, Chailler P, D'Orléans-Juste P, Sirois P, Brière N. Growth regulatory properties of endothelins. Peptides 1993; 14: 385-399.
6. 6. Rubanyi G M, Polokoff M A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325-415.
7. 7. Sakurai T, Yanagisawa M, Masaki T: Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992; 13: 103-108.
8. 8. Goldie R G. Endothelin receptor subtypes: Distribution and function in the lung. Pulm Pharmacol Ther 1998; 11: 89-95.
9. 9. Karne S, Jayawickreme C K, Lerner M R. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem 1993; 268: 19126-19133.
10. 10. Warner T D, Allcock G H, Mickley E J, Corder R, Vane J R. Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol 1993; 22: S117-S120.
11. 11. Kumar C S, Nuthulaganti P, Pullen M, Nambi P. Novel endothelin receptors in the follicular membranes of Xenopus laevis oocytes mediate calcium responses by signal transduction through gap junctions. Mol Pharmacol 1993; 44: 153-157.
12. 12. Nambi P, Pullen M, Kumar C: Identification of a novel endothelin receptor in Xenopus laevis liver. Neuropeptides 1994; 26: 181-185.
13. 13. Bax W A, Saxena P R. The current endothelin receptor classification: time for reconsideration? Trends Pharmacol Sci 1994; 15: 379-386.
14. B receptor subtypes in the dog kidney. J Cardiovasc Pharmacol 1995; 26: S322-S325.
15. 15. Masaki T, Vane J R, Vanhoutte P M. V International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev 1994; 46: 137-142.
16. 16. Ruiz-Opazo N, Hirayama K, Akimoto K, Herrera V L M. Molecular characterization of a dual ET-1/AII receptor. Mol Med 1998; 4: 96-108.
17. 17. De Nucci G, Thomas R, D'Orléans-Juste P, Antunes E, Walder C, Warner T D, Vane J R. Pressor effect of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85: 9797-9800.
18. 18. Moreland S, McMullen D M, Delaney C L, Lee V G, Hunt J T. Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun 1992; 84: 100-106.
19. 19. Seo B, Oemar B S, Siebenmann R, von Segesser L, Luscher T F. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circ 1994; 89: 1203-1208.
20. 20. Teerlink J R, Breu V, Sprecher U, Clozel M, Clozel J P. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res 1994; 74: 105-114.
21. 21. Maggi C A, Giuliani S, Patacchini R, Rovero P, Giachetti A, Meli A. The activity of peptides of the endothelin family in various mammalian smooth muscle preparations. Eur J Pharmacol 1989; 174: 23-31.
22. A receptors predominate in the human vasculature and mediate constriction. J Cardiovasc Pharmacol 1995; 26: S265-S267.
23. 23. Battistini B, D'Orléans-Juste P, Sirois P. Endothelins in physiopathology; circulating plasma levels and presence in other biological fluids. Lab Invest 1993; 68: 600-628.
24. 24. Battistini B, Botting R, Warner T D. Endothelin: a knockout in London. Trends Pharmacol Sci 1995; 16: 217-222.
25. 25. Benigni A, Remuzzi G. Endothelin receptor antagonists: which are the therapeutic perspectives in renal diseases? Nephrol Dial Transplant 1998; 13: 5-7.
26. 26. Webb D J, Strachan F E. Clinical experience with endothelin antagonists. Am J Hypertens 1998; 11: S71-S79.
27. 27. Douglas S A. Clinical developments of endothelin receptor antagonists. Trends Pharmacol Sci 1997; 18: 408-412.
28. 28. Webb D J, Monge J C, Rabelink T J, Yanagisawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci 1998; 19: 5-8.
29. 2+-mobilizing, and mitogenic effects of endothelin and vasoactive intestinal contractor in mouse 3T3 cells. J Cell Physiol 1990; 145: 88-94.
30. 30. Ihara M, Fukuroda T, Saeki T, Nishikibe M, Kojiri K, Suda H, Yano M. An endothelin receptor (ETA) antagonist isolated from streptomyces misakiensis. Biochem Biophys Res Commun 1991; 178: 132-137.
31. 31. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, Fukami T, Ishikawa K, Nishikibe M, Yano M. Biological profiles of highly potent novel endothelin antaganists selective for the ETA receptor. Life Sci 1991; 50: 247-255.
32. 32. Miyata S, Hashimoto M, Fujie K, Nishikawa M, Kiyoto S, Okuhara M, Koshaka M. WS-7338, new endothelin receptor antaganists isolated from Streptomyces sp. No. 7338. II. Biological characterization and pharmacological characterization of WS-7338 B. J Antiobiot Tokyo 1991; 45: 83-87.
33. 33. Miyata S, Fukami N, Neya M, Takase S, Kiyoto S. WS-7338, new endothelin receptor antagonists isolated from Streptomyces sp. No. 7338. III. Structures of WS-7338 A, B, C and D and total synthesis of WS-7338. J Antibiot Tokyo 1992; 45: 788-791.
34. 34. Miyata S, Hashimoto M, Masui Y, Ezaki M, Takase S, Nishikawa M, Kiyoto S, Okuhara M, Kohsaka M. WS-7338, new endothelin receptor antagonists isolated from Streptomyces sp. No. 7338. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot Tokyo 1992; 45: 74-82.
35. 35. Fukuroda T, Nishikibe M, Ohta Y, Ihara M, Yano M, Ishikawa K, Fukami T, Ikemoto F. Analysis of responses to endothelins in isolated porcine blood vessels by using a novel endothelin antagonist, BQ-153. Life Sci 1992; 50: PL107-PL112.
36. 36. Itoh S, Sasaki T, Ide K, Ishikawa K, Nishikibe M, Yano M. A novel endothelin ETA receptor antagonist, BQ-485, and its preventive effect on experimental cerebral basospasm in dogs. Biochem Biophys Res Commun 1993; 195: 969-975.
37. 37. Ishikawa K, Fukami T, Nagase T, Mase T, Hayama T, Niiyama K, Fujita K, Urakawa Y, Kumagai U, Fukuroda T, Ihara M, Yano M. Endothelin antagonistic peptide derivatives with high selectivity for ETA receptors. In: Schneider C H, Eberle A N, eds. Peptides. ESCOM Sci Publishers BV, 1992; 685-686.
38. 38. Aramori I, Nirei H, Shoubo M, Sogabe K, Nakamura K, Hojo H, Notsu Y, Ono T, Nakanishi S. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected chinese hamster ovary cells. Mol Pharmacol 1993; 43: 127-131.
39. 39. Sogabe K, Nirei H, Shoubo M, Nomoto A, Ao S, Notsu Y, Ono T. Pharmacological profile of FR139917, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther 1993; 264: 1040-1046.
40. 40. Miyata S, Hashimoto M, Fujie K, Shouho M, Sogabe K, Kiyoto S, Okuhara M, Koshaka M. WS009 A and B, new endothelin receptor antoganists isolated from streptomyces sp. No. 89009. II. Biological characterization and pharmacological characterisation of WS009 A and B. J Antibiot Tokyo 1992; 45: 1041-1046.
41. 41. Fujimoto M, Mihara S, Nakajima S, Ueda M, Nakamura M, Sakurai K. A novel non-peptide endothelin antagonist isolated from bayberry myrica cerifera. FEBS Lett 1992; 305: 41-44.
42. 42. Maguire J J, Bacon C R, Fujimoto M, Davenport A P. Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors. J Hypertens 1994; 12: 675-680.
43. 43. Mihara S, Fujimoto M. The endothelin ETA receptor-specific effect of 50-235, a non-peptide endothelin antagonist. Eur J Pharmacol 1993; 246: 33-38.
44. 44. Mihara S, Nakajima S, Matumura S, Kohnoike R, Fujimoto M. Pharmacological characterization of a potent nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 268: 1122-1128.
45. 45. Chan M, Balaji V. (1993) WO 9323404. Patent.
46. 46. Chan M F, Okun I, Stavros F L, Hwang E, Wolff M E, Balaji V N. Identification of a new class of ETA selective endothelin antagonists by pharmacophore directed screening. Biochem Biophys Res Commun. 1994; 201: 228-234.
47. 47. VonGeldern T W, et al. (1993) WO 9508550. Patent.
48. 48. Quin J, et al. (1995) 209th ACS meeting, April 2-6, Anaheim, California, MEDI 157 (Abst.)
49. 49. Lee C, et al. (1995) 209th ACS meeting, April 2-6, Anaheim, California, MEDI 160 (Abst.).
50. 50. Astles P C, et al. (1994) Rhône-Poulenc Rorer, Filed Int. November WO 9513262.
51. 51. Ohashi H, Akiyama H, Nishikori K, Mochizuki J. Asterric acid, a new endothelin binding inhibitor. J Antibiot Tokyo 1992; 45: 1684-1685.
52. 52. Stein P D, Hunt J T, Floyd D M, Moreland S, Dickinson K E J, Mitchell C, Liu E C K, Webb M L, Murugesan N, Dickey J, McMullen D, Zhang R, Lee V G, Serafino R, Delaneu C, Schaeffer T R, Zolowsky M. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazoly)-1-naphthalenesulfonamide. J Med Chem 1994, 37: 329-331.
53. 53. Webb M L, Bird J E, Liu E C K, Rose P M, Serafino R, Stein P D, Moreland S. BMS-182874 is a selective, non-peptide endothelin ETA receptor antagonist. J Pharmacol Exp Therap 1995; 272: 1124-1134.
54. 54. Ferrer P, Valentine M, Jenkins-West T, Weber H, Goller N L, Durham S K, Molloy C J, Moreland S. Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries. J Cardiovasc Pharmacol 1995; 26: 908-915.
55. 55. Yu M, Gopalakrishnan V, McNeill J R. Hemodynamic effects of a selective endothelin - a receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats. J Cardiovasc Pharmacol 1998; 31: S262-S264.
56. 56. Snapper J R, Thabes J S, Lefferts P L, Lu W. Role of endothelin in endotoxin-induced sustained pulmonary hypertension in sheep. Am J Respir Crit Care Med 1998; 157: 81-88.
57. 57. Bradbury R H, Bath C, Butlin R J, Dennis M, Heys C, Hunt S J, James R, Mortlock A A, Sumner N F, Tang E K, Telford B, Whiting E, Wilson C. New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and-N-pyrazinyl-1-naphthalenesulfonamides. J Med Chem 1997; 40: 996-1004.
58. 58. Doherty A M, Patt W C, Edmunds J J, Berryman K A, Reisdorph B R, Plummer M S, Shahripour A, Lee C, Cheng X M, Walker D M. Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. J Med Chem 1995; 38: 1259-1263.
59. 59. Doherty A M, Patt W C, Repine J, Edmunds J J, Berryman K A, Reisdorph B R, Walker D M, Haleen S J, Keiser J A, Flynn M A. Structure-activity relathionships of a novel series of orally active nonpeptide ETA and ETA/B endothelin receptor-selective antagonists. J Cardiovasc Pharmacol 1995; 26: S358-S361.
60. 60. Reynolds E E, Hwang O, Flynn M A, Welch KMN, Cody W L, Steinbaugh B, He J X, Chung F Z, Doherty A M. Pharmacological differences between rat and human endothelin B receptors. Biochem Biophys Res Commun 1995; 209: 506-512.
61. 61. Reynolds E E, Keiser J A, Haleen S J, Walker D M, Olszewski B, Schroeder R L, Taylor D G, Hwang O, Welch KMN, Flynn M A. Pharmacological characterization of PD156707, an orally active ETA receptor antagonist. J Pharmacol Exp Ther 1995; 273: 1410-1417.
62. 62. Patel T R, Galbraith S, Graham D I, Hallak H, Doherty A M, McCulloch J. Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia. J Cereb Blood Flow Metab 1996; 16: 950-958.
63. 63. Bunker A M, et al. (1995) 210th ACS meeting, Chicago, Illinois, MEDI 37 (Abst.)
64. 64. Bishop P. Poster Highlights of the Medicinal Chemistry XVth EFMC International Symposium (Part V). 6-10 September 1998, Edinburgh, Scotland, UK. Investigational Drugs Weekly Highlights. 39:29.
65. 65. Georgia B McGaughey. Highlights From the Divisions of Computers in Chemistry and Medicinal Chemistry, American Chemical Society 216th National Meeting (Part XXII). 23-27 August 1998, Boston, MA, USA. Investigational Drugs Weekly Highlights. 38:20.
66. 66. Opgenorth T J, Adler A L, Calzadilla S V, Chiou W J, Dayton B D, Dixon D B, Gehrke L J, Hernandez L, Magnuson S R, Marsh K C. Novosad E I, von Geldern T W, Wessale J L, Win M, Wu-Wong J R. Pharmacological characterization of A-127722: An orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996; 276: 473-481.
67. 67. Winn M, von Geldern T W, Opgenorth T J, Jae H S, Tasker A S, Boyd S A, Kester J A, Mantei R A, Bal R, Sorensen B K, Wu-Wong J R, Chiou W J, Dixon D B, Novosad E I, Hernandez L, Marsh K C. 2,4-Diarylpyrrolidine-3-carboxylic acids - potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. J Med Chem 1996; 39: 1039-1048.
68. 68. Liu G, Henry K J Jr, Szczepankiewicz B G, Winn M, Kozmina N S, Boyd S A, Wasicak J, von Geldern T W, Wu-Wong J R, Chiou W J, Dixon D B, Nguyen B, Marsh K C, Opgenorth T J . Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546). J Med Chem 1998; 41: 3261-3275.
69. 69. Bialecki R A, Stinson-Fisher C, Murdoch W, Bertelson D, Desiato M, Rumsey W. A novel orally active ET-A receptor antagonist, ZD1611, prevents chronic hypoxia-induced pulmonary hypertension in the rat. Chest 1998; 114: S91.
70. 70. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel J P, Clozel M. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997; 283: 1110-1118.
71. 71. Ohlstein E H, Nambi P, Hay D W, Gellai M, Brooks D P, Luengo J, Xiang J N, Elliott J D. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist. J Pharmacol Exp Ther 1998; 286: 650-656.
72. B receptor antagonism in a locally injured canine coronary artery. Eur J Pharmacol 1998; 341: 187-190.
73. 73. Benigni A, Corna D, Maffi R, Benedetti G, Zoja C, Remuzzi G. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 1998; 54: 353-359.
74. 74. Birck R, Knoll T, Braun C, Kirchengast M, Münter K, van der Woude F J, Rohmeiss P. Improvement of postischemic acute renal failure with the novel orally active endothelin-A receptor antagonist LU 135252 in the rat. J Cardiovasc Pharmacol 1997; 32: 80-86.
75. 75. Gonon A T, Wang Q D, Shimizu M, Pernow J. The novel non-peptide selective endothelin A receptor antagonist LU 135,252 protects against myocardial ischaemic and reperfusion injury in the pig. Acta Physiol Scand 1998; 163: 131-137.
76. 76. Wu C, Chan M F, Stavros F, Raju B, Okun I, Mong S, Keller K M, Brock T, Kogan T P, Dixon R A. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997; 40: 1690-1697.
77. 77. Verner E J, Kois A, Raju B, Wu C, Venkatachalapathie Y V, Castillo R, Hwang E, Okun I, Stravos F D, Balaji V N, Wolff M E, Chan M F. Design and synthesis of benzenesulfonamides as endothelin antagonists. ImmunoPharmaceutics Inc.
78. 78. Karaki H, Sudjarwo S A, Hori M, Sakata K, Urade Y, Takai M, Okada T. ETB receptor antagonist, IRL 1038, selectively inhibits the endothelin-induced endothelium-dependent vascular relaxation. Eur J Pharmacol 1993; 231: 371-374.
79. 79. Balwierczak J L, Bruseo C W, DelGrande D, Jeng A Y, Savage P, Shetty S S. Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500. J Cardiovasc Pharmacol 1995; 26: S393-S396.
80. 80. Morishita Y, Chiba S, Tsukuda E, Tanaka T, Ogawa T, Yamasaki M, Yoshida M, Kawamoto I, Matsuda Y RES-701-1, a novel and selective endothelin type B receptor antagonist produced by Streptomyces sp. RE-701. I. Characterization of producing strain, fermentation, isolation, physico-chemical and biological properties. J Antibiot Tokyo 1994; 47: 269-275.
81. 81. Yamasaki M, Yano K, Yoshida M, Matsuda Y, Yamaguchi K. RES-701-1, a novel and selective endothelin type B receptor antagonist produced by Streptomyces sp. RE-701. II. Determination of the primary sequence. J Antibiot Tokyo 1994; 47: 276-280.
82. 82. Tanaka T, Ogawa T, Matsuda Y Species difference in the binding characteristics of RES-701-1: potent endothelin ETB receptor-selective antagonist. Biochem Biophys Res Commun 1995; 209: 712-716.
83. 83. Ogawa T, Ochiai K, Tanaka T, Tsukuda E, Chiba S, Yano K, Yamasaki M, Yoshida M, Matsuda Y RES-701-2, -3 and -4, novel and selective endothelin type B receptor antagonists produced by Streptomyces sp. I. Taxonomy of producing strains, fermentation, isolation, and biochemical properties. J Antibiot Tokyo 1995; 48: 1213-1220.
84. 84. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, Nishikibe M, Yano M. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Med Sci 1994; 91: 4892-4896.
85. 85. Fukuroda T, Ozaki S, Ihara M, Ishikawa K, Yano M, Nishikibe M. Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery. Br J Pharmacol 1994; 113: 336-338.
86. 86. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994; 199: 1461-1465.
87. 87. Fukami T, Yamakawa T, Kojima H, Amano Y, Ihara M, Yano M, Ishikawa K. Synthesis of 2-substituted D-Tryptophan-containing peptide derivatives with endothelin receptor antagonist activity. Bioorg Med Chem Lett 1995; 5: 1483-1488.
88. 88. Fukami T, Yamakawa T, Niiyama K, Kojima H, Amano Y, Kanda F, Ozaki S, Fukuroda T, Ihara M, Yano M, Ishikawa K. Synthesis and structure-activity relationships of 2-substituted D-tryptophan-containing peptidic endothelin receptor antagonists: importance of the C-2 substituent of the D-tryptophan residue for endothelin A and B receptor subtype selectivity. J Med Chem 1996; 39: 2313-2330.
89. 89. Breu V, Clozel M, Burri K, Hirth G, Neidhart W, Ramuz H. In vitro characterization of Ro 46-8443, the first non-peptide antagonist selective for the endothelin ETB receptor. FEBS Lett 1996; 383: 37-41.
90. 90. Cody W L, Doherty A M, He J X, DePue P L, Waite L A, Topliss J G, Haleen S J, LaDouceur D, Flynn M A, Hill K E, Reynolds E E. The rational design of a highly potent combined ETA and ETB receptor antagonist (PD 145065) and related analogues. Med Chem Res 1993; 3: 154-162.
91. 91. Nakajima Y, Kizawa Y, Nakano J, Kotake H, Inami T, Kusama T, Murakami H. Effects of ET antagonists (PD143296 and PD145065) on contractions in guinea pig hilar bronchus induced by endothelin-1 and its related peptide. Receptor 1995; 5: 177-183.
92. 92. Cody W L, Doherty A M, He J X, DePue P L, Rapundalo S T, Hingorani G A, Major T C, Panek R L, Dudley D T, Haleen S J. Design of a functional hexapeptide antagonist of endothelin. J Med Chem 1992; 35: 3301-3303.
93. 93. Doherty A M, Cody W L, He J X, DePue P L, Cheng X M, Welch K M, Flynn M A, Reynolds E E, LaDouceur D M, Davis L S, et al. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol 1993; 22: S98-S102.
94. 94. Cody W L, He J X, Reily M D, Haleen S J, Walker D M, Reyner E L, Stewart B H, Doherty A M. Design of a potent combined pseudopeptide ET-A/ET-B receptor antagonist, Ac-DBgh16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): Examination of its pharmacokinetics and spectral properties. J Med Chem 1997; 40: 2228-2240.
95. 95. Clozel M, Breu V, Gray G A, Löffler B M. In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol 1993; 22: S377-S379.
96. 96. Clozel M, Breu V, Burri K, Cassai J M, Fischli W, Gray G A, Hirth G, Loffler B M, Muller M, Neidhart W, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365: 759-761.
97. 97. Breu V, Loffler B M, Clozel M. In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett 1993; 334: 210-214.
98. 98. Clozel M, Breu V, Gray G A, Kalina B, Löffler B M, Burri K, Cassal J M, Hirth G, Muller M, Neidhart W. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228-235.
99. 99. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 1995; 268: H828-H835.
100. 100. Richard V, Kaeffer N, Hogie M, Tron C, Blanc T, Thuillez C. Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist. Br J Pharmacol 1994; 113: 869-876.
101. 101. Mugrage B, Molitemi J, Webb R L, Shetty S S, Lipson K E, Chin M H, Neale R, Cioffi C. CGS27830, a potent nonpeptide endothelin receptor antagonist. Bioorg Med Chem Lett 1993; 3: 1099-2104.
102. 102. Chin M H, Cioffi C L, Garay M, Neale R F, Shetty S S, DelGrande D, Mugrage B, Sills M A, Lipson K E. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions. J Pharmacol Exp Ther 1996; 276: 74-83.
103. 103. Ohlstein E H, Nambi P, Douglas S A, Edwards R M, Gellai M, Lago A, Leber J D, Cousins R D, Gao A, Frazee J S, Peishoff C E, Bean J W, Eggleson D S, Elshourbagy N A, Kumar C, Lee J A, Y T-I, Louden C, Brooks D P, Weinstock J, Feuerstein G, Poste G, Ruffolo R R Jr, Gleason J G, Elliott J D. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Pharmacol 1994; 91: 8052-8056.
104. 104. Ohlstein E H, Beck G R Jr, Douglas S A, Nambi P, Lago M A, Gleason J G, Ruffolo R R Jr, Feuerstein G, Elliott J D. Nonpeptide endothelium receptor antagonists. II. Pharmacological characterisation of SB 209670. J Pharmacol Exp Ther 1994; 271: 762-768.
105. 105. Elliott J D, Lago A, Cousins R D, Gao A, Leber J D, Erhard K F, Nambi P, Elshourbagy N A, Kumar C, Lee J A, Bean J W, DeBrosse C W, Eggleston D S, Brooks D P, Feuerstein G, Ruffolo R R Jr, Weinstock J, Gleason J G, Peishoff C E, Ohlstein E H. 1,3-diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists. J Med Chem 1994; 37: 1553-1557.
106. 106. Brooks D P, dePalma P D, Gellai M, Nambi P, Ohlstein E H, Elliott J D, Gleason J G, Ruffolo R R Jr. Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ-123 on acute renal failure in anesthetized dogs. J Pharmacol Exp Ther 1994; 271: 769-775.
107. 107. Douglas S A, Louden C, Vickery-Clark L M, Storer B L, Hart T, Feuerstein G Z, Elliott J D, Ohlstein E H. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res 1994; 75: 190-197.
108. 108. Willette R N, Zhang H, Mitchell M P, Sauermelch C F, Ohlstein E H, Sulpizio A C. Nonpeptide endothelin antagonist. Cerebrovascular characterization and effects on delayed cerebral vasospasm. Stroke 1994; 25: 2450-2455.
109. 109. Ohlstein E H, Nambi P, Lago M A, Hay DWP, Beck G, Fong K-L, Eddy E P, Smith P, Ellens H, Elliott J D. Nonpeptide endothelin recpetor antagonists. VI. Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 1996; 276: 609-615.
110. B. J Med Chem 1993; 36: 4087-4093.
111. B. 1994; 200: 1708-1712.
112. 112. Masuda Y, Sugo T, Kikuchi T, Kawata A, Satoh M, Fujisawa Y, Itoh Y, Wakimasu M, Ohtaki T. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperasin-1-yl)carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelin-A and endothelin-B receptors. J Pharmacol Exp Ther 1996; 279: 675-685.
113. 113. Kusumoto K, Fujiwara A, Ikeda S, Watanabe T, Fujino M. Pharmacological characterization of cardiovascular responses induced by endothelin-1 in the perfused rat heart. Eur J Pharmacol 1996; 296: 65-74.
114. B receptor antagonist blocks proliferation of rat vascular smooth muscle cells after balloon angioplasty. Life Sci 1995; 56: PL449-PL454.
115. B receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol 1995; 114: 949-954.
116. 116. Haynes W G, Ferro C J, O'Kane K P, Somerville D, Lomax C C, Webb D J. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93: 1860-1870.
117. 117. Ferro C J, Haynes W G, Johnston N R, Lomax C C, Newby D E, Webb D J. The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction. Br J Clin Pharmacol 1997; 44: 377-383.
118. 118. Patt W C, Edmunds J J, Repine J, Berryman K A, Reisdorph B R, Lee C, Plummer M S, Chahripour A, Haleen S J, Keiser J A, Flynn M A, Welch K M, Reynolds E E, Rubin R, Tobias B, Hallak H, Doherty A . Structure-activity relationship in a series of orally active gamma-hydroxy butenolide endothelin antagonists. J Med Chem 1997; 40: 1063-1074.
119. 119. Davenport A P, Kuc R E, Ashby M J, Patt W C, Doherty A M. Characterization of [125I]-PD164333, an ETA selective non-peptide radiolabelled antagonist, in normal and diseased human tissues. Br J Pharmacol 1998; 123: 223-230.
120. 120. Williams D L Jr, Murphy K L, Nolan N A, O'Brien J A, Pettibone D J, Kivlighn S D, Krause S M, Lis E V Jr, Zingaro G J, Gabel R A. Pharmacology of L-754,142, a highly potent, orally active, non-peptidyl endothelin antagonist. J Pharmacol Exp Ther 1995; 275: 1518-1526.
121. B endothelin antagonist, L-754,142, after aortic cross-clamping in the dog. J Am Soc Nephrol 1997; 8: 1061-1071.
122. B receptors. Life Sci 1995; 56: 1251-1256.
123. 123. De Lombaert S, Blanchard L, Berry C, Ghai R D, Trapani A J. Non-peptidic inhibitors of neutral endopeptidase 24.11. 2. Design and pharmacology of orally active phorphonate prodrugs. Bioorg Med Chem Lett 1995; 5: 151-154.
124. 124. De Lombaert S, Blanchard L, Tan J, Sakane Y, Berry C, Ghai R D. Non-peptidic inhibitors of neutral endopeptidase 24.11. I. Discovery and optimization of potency. Bioorg Med Chem Lett 1995; 5: 145-150.
125. 125. De Lombaert S, Ghai R D, Jeng A Y, Trapani A J, Webb R L. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem Biophys Res Commun 1994; 204: 407-412.
126. 126. Vemulapalli S, Chintala M, Stamford A, Watkins R, Chiu P, Sybertz E, Fawzi A B. Renal effects of SCH 54470: A triple inhibitor of ECE, ACE, and NEP. Cardioavsc Drug Rev 1997; 15: 260-272.
127. 127. McKittrick B A, Standford A W, Weng X. Design and synthesis of phosphoric acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11. Bioorg Med Chem Lett 1996; 6: 1629-1634.
128. 128. Ahn K, Sisneros A M, Herman S B, Pan S M, Hupe D, Lee C, Nikam S, Cheng X M, Doherty A M, Schroeder R L, Haleen S J, Kaw S, Emoto N, Yanagisawa M. Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Commun 1998; 243: 184-190.
129. 129. Spinella M J, Malik A B, Everitt J, Andersen T T. Design and synthesis of a specific endothelin 1 antagonist: effects on pulmonary vasoconstriction. Proc Natl Acad Sci USA 1991; 88: 7443-7446.
130. 130. Lam Y K T, Williams D L Jr, Sigmund J M, Snachez M, Genilloud O, Kong Y L, Stevens-Miles S, Huang L, Garrity G M. Cochinmicins, novel and potent cyclodepsipeptide endothelin antagonists from a microbispora sp. I. Production, isolation, and characterisation. J Antibiot Tokyo 1992; 45: 1709-1716.
131. 131. Kitada C, Ohtaki T, Masuda Y, Masuo Y, Momura H, Asami T, Matsumoto Y, Satou M, Fujino M. Design and synthesis of ETA receptor antagonists and study of ETA receptor distribution. J Cardiovasc Pharmacol 1993; 22: S128-S131.
132. 132. Katwa L C, Guarda E, Weber K T. Endothelin receptors in cultures adult rat cardiac fibroblasts. Cardiovasc Res 1993; 27: 2125-2129.
133. 133. Gulavita N, Wright A E, McCarthy P J, Pomponi S A, Kelly-Borges M. Isolation and structure elucidation of 34-sulfatobastadin 13, an inhibitor of the endothelin a receptor, from a marine sponge of the genus ianthella. J Natural Products 1993; 56: 1613-1617.
134. 134. Jackson M, Burres N S, Karwowski J P, Alder L A, Humphrey P E, Kohl W L, McAlpine J B. Aselacins, novel compounds that inhibit binding of endothelin to its receptor. I. The producing organism, fermentation and biological activity. J Antibiot Tokyo 1994; 47: 523-528.
135. 135. Williams D L Jr, Murphy K L, Nolan N A, O'Brien J A, Lis E V Jr, Pettibone D J, Clineschmidt B V, Krause S M, Veber D F, Naylor E M, Chakravarty P K, Walsh T F, Dhanoa D M, Chen A, Bagley S W, Fitch K J, Greenlee W J. Pharmacology of L-744453, a novel nonpeptidyl endothelin antagonist. Life Sci 1996; 58: 1149-1157.
136. 136. Hoshino T, Yamauchi R, Kikkawa K, Yabana H, Murata S. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist. J Pharmacol Exp Ther 1998; 286: 643-649.
137. 137. Ohnishi M, Wada A, Tsutamoto T, Fukai D, Sawaki M, Maeda Y, Kinoshita M. Chronic effects of a novel, orally active endothelin receptor antagonist, T-0201, in dogs with congestive heart failure. J Cardiovasc Pharmacol 1998; 31: S236-S238.